Hepatologie 2008

Was ist neu?

Virushepatitis:

• Tenofovir bei Hepatitis B

• Vakzineentwicklung bei Hepatitis C

• chronischer Verlauf der Hepatitis E bei Transplantatempfängern

Alkoholhepatitis:

• Neues prognostisches Modell

Leberzirrhose:

• Transiente Elastographie zur Abgrenzung einer Fibrose

• Norfloxacin zur Primärprophylaxe der spontan bakteriellen Peritonitis

Hepatozelluläres Karzinom:

• Protektive Rolle von Östrogenen und Kaffee

• Radiofrequenzthermoablation und Resektion bei kleinen Karzinomen gleichwertig

• Cholangiozelluläres Karzinom

• Hepatitis C, nicht-alkoholische und alkoholische Lebererkrankungen, Übergewicht und Rauchen als Risikofaktoren

Literatur

• 1 Allen K J, Gurrin L C, Constantine C C. et al . Iron-overload-related disease in HFE hereditary hemochromatosis.  N Engl J Med. 2008;  358 221-230
• 2 Bravi F, Bosetti C, Tavani A. et al . Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.  Hepatology. 2007;  46 430-435
• 3 Cheng B Q, Jia C Q, Liu C T. et al . Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.  JAMA. 2008;  299 1669-1677
• 4 Dalgard O, Bjoro K, Ring-Larsen H. et al . Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.  Hepatology. 2008;  47 35-42
• 5 Fernandez J, Navasa M, Planas R. et al . Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.  Gastroenterology. 2007;  133 818-824
• 6 Friedrich-Rust M, Ong M F, Martens S. et al . Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.  Gastroenterology. 2008;  134 960-974
• 7 Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient.  N Engl J Med. 2008;  358 859-860
• 8 Haagsma E B, van den Berg A P, Porte R J. et al . Chronic hepatitis E virus infection in liver transplant recipients.  Liver Transpl. 2008;  14 547-553
• 9 Hui C K, Zhang H Y, Bowden S. et al . 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.  J Hepatol. 2008;  48 714-720
• 10 Jacobson I M. Combination therapy for chronic hepatitis B: Ready for prime time?.  J Hepatol. 2008;  48 687-691
• 11 Kamar N, Selves J, Mansuy J M. et al . Hepatitis E virus and chronic hepatitis in organ-transplant recipients.  N Engl J Med. 2008;  358 811-817
• 12 Kim W R, Flamm S L, Di Bisceglie A M. et al . Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.  Hepatology. 2008;  47 1363-1370
• 13 Kulik L M, Carr B I, Mulcahy M F. et al . Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.  Hepatology. 2008;  47 71-81
• 14 Lai C L, Gane E, Liaw Y F. et al . Telbivudine versus lamivudine in patients with chronic hepatitis B.  N Engl J Med. 2007;  357 2576-2588
• 15 Lai M, Hyatt B J, Nasser I. et al . The clinical significance of persistently normal ALT in chronic hepatitis B infection.  J Hepatol. 2007;  47 760-767
• 16 Lampertico P, Vigano M, Manenti E. et al . Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.  Gastroenterology. 2007;  133 1445-1451
• 17 Larsson S C, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis.  Gastroenterology. 2007;  132 1740-1745
• 18 Law M, Maruyama T, Lewis J. et al . Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.  Nat Med. 2008;  14 25-27
• 19 Lin C L, Liao L Y, Liu C J. et al . Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.  Hepatology. 2007;  45 1193-1198
• 20 Livraghi T, Meloni F, Di Stasi M. et al . Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?.  Hepatology. 2008;  47 82-89
• 21 Llovet J, Rici S, Mazzaferro V. et al . Randomized phase III trial of sorafenib versus plazebo in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 LBA1
• 22 Louvet A, Naveau S, Abdelnour M. et al . The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.  Hepatology. 2007;  45 1348-1354
• 23 Mangia A, Minerva N, Bacca D. et al . Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.  Hepatology. 2008;  47 43-50
• 24 McHutchison J G, Dusheiko G, Shiffman M L. et al . Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.  N Engl J Med. 2007;  357 2227-2236
• 25 McMullan L K, Grakoui A, Evans M J. et al . Evidence for a functional RNA element in the hepatitis C virus core gene.  Proc Natl Acad Sci U S A. 2007;  104 2879-2884
• 26 Naugler W E, Sakurai T, Kim S. et al . Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.  Science. 2007;  317 121-124
• 27 Pedersen I M, Cheng G, Wieland S. et al . Interferon modulation of cellular microRNAs as an antiviral mechanism.  Nature. 2007;  449 919-922
• 28 Romero-Gomez M, Cordoba J, Jover R. et al . Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.  Hepatology. 2007;  45 879-885
• 29 Sagir A, Erhardt A, Schmitt M. et al . Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.  Hepatology. 2008;  47 592-595
• 30 Shaib Y H, El-Serag H B, Nooka A K. et al . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.  Am J Gastroenterol. 2007;  102 1016-1021
• 31 Sung J J, Lai J Y, Zeuzem S. et al . Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.  J Hepatol. 2008;  48 728-735
• 32 Tan J, Degertekin B, Wong S N. et al . Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.  J Hepatol. 2008;  48 391-398
• 33 Thimme R, Spangenberg H C, Blum H E. Chronic hepatitis B.  Dtsch Med Wochenschr. 2008;  133 135-138
• 34 Wedemeyer H, Cornberg M, Protzer U. et al . German guidelines on diagnosis and therapy of hepatitis B.  Dtsch Med Wochenschr. 2007;  132 1775-1782
• 35 Welzel T M, Mellemkjaer L, Gloria G. et al . Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study.  Int J Cancer. 2007;  120 638-641
• 36 Yuen M F, Fong D Y, Wong D K. et al . Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response.  Hepatology. 2007;  46 1695-1703